Cargando…

The Difference in Clinical Behavior of Gene Fusions Involving RET/PTC Fusions and THADA/IGF2BP3 Fusions in Thyroid Nodules

SIMPLE SUMMARY: Around 25% of patients who undergo an ultrasound-guided thyroid biopsy end up with an indeterminate result based on cytology. This has propelled the use of other modalities, such as molecular testing, to further stratify these patients. The aim of our retrospective study was to repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tali, George, Payne, Alexandra E., Hudson, Thomas J., da Silva, Sabrina Daniela, Pusztaszeri, Marc, Tamilia, Michael, Forest, Véronique-Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340223/ https://www.ncbi.nlm.nih.gov/pubmed/37444504 http://dx.doi.org/10.3390/cancers15133394

Ejemplares similares

MON-514 Detection of RAS Mutations and RET/PTC Fusions in Thyroid Cancer Using Microfluidic Digital PCR
por: Ylli, Dorina, et al.
Publicado: (2020)

Coexisting Molecular Alterations Increase the Risk of Malignancy in Thyroid Nodules with Copy Number Alterations
por: Rajab, Mohannad, et al.
Publicado: (2022)

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?
por: Turkdogan, Sena, et al.
Publicado: (2020)

A Multifocal Pediatric Papillary Thyroid Carcinoma (PTC) Harboring the AGK-BRAF and RET/PTC3 Fusion in a Mutually Exclusive Pattern Reveals Distinct Levels of Genomic Instability and Nuclear Organization
por: Sisdelli, Luiza, et al.
Publicado: (2021)

The Mcgill thyroid nodule score – does it help with indeterminate thyroid nodules?
por: Varshney, Rickul, et al.
Publicado: (2015)

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
por: Estrada-Zuniga, Cynthia M., et al.
Publicado: (2022)

A study to evaluate association of nuclear grooving in benign thyroid lesions with RET/PTC1 and RET/PTC3 gene translocation
por: Ashwini, Basavaraj Rangalakshmi, et al.
Publicado: (2023)

Molecular Testing for Thyroid Nodules: The Experience at McGill University Teaching Hospitals in Canada
por: Rajab, Mohannad, et al.
Publicado: (2022)

Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis
por: Cyniak-Magierska, Anna, et al.
Publicado: (2011)

The McGill Thyroid Nodule Score’s (MTNS+) role in the investigation of thyroid nodules with benign ultrasound guided fine needle aspiration biopsies: a retrospective review
por: Khalife, Sarah, et al.
Publicado: (2016)

ret/PTC-1 expression alters the immunoprofile of thyroid follicular cells
por: Denning, Karen, et al.
Publicado: (2008)

Does the likelihood of malignancy in thyroid nodules with RAS mutations increase in direct proportion with the allele frequency percentage?
por: Hudson, Thomas J., et al.
Publicado: (2023)

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers
por: Eszlinger, Markus, et al.
Publicado: (2021)

RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis
por: Bulanova Pekova, Barbora, et al.
Publicado: (2023)

Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis
por: Su, Xuan, et al.
Publicado: (2016)

RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma
por: Romei, Cristina, et al.
Publicado: (2012)

Surgical Outcomes of Thyroid Nodules Positive for Gene Expression Alterations Using ThyroSeq V3 Genomic Classifier
por: Salameh, Samer, et al.
Publicado: (2022)

Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer
por: Chen, Mengke, et al.
Publicado: (2023)

Identification and characterization of RET fusions in advanced colorectal cancer
por: Le Rolle, Anne-France, et al.
Publicado: (2015)

Cystic brain metastases and RET fusion in lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

Effect of Having Concurrent Mutations on the Degree of Aggressiveness in Patients with Thyroid Cancer Positive for TERT Promoter Mutations
por: Alohali, Sama, et al.
Publicado: (2023)

Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review
por: Hier, Jessica, et al.
Publicado: (2021)

RET/PTC and CK19 Expression in Papillary Thyroid Carcinoma and Its Clinicopathologic Correlation
por: Shin, Eunah, et al.
Publicado: (2005)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

The role of repeat fine needle aspiration in the management of indeterminate thyroid nodules
por: Jooya, Alborz, et al.
Publicado: (2016)

RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
por: Gozgit, Joseph M., et al.
Publicado: (2018)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
por: Nagasaka, Misako, et al.
Publicado: (2023)

DNA Breaks at Fragile Sites Generate Oncogenic RET/PTC Rearrangements in Human Thyroid Cells
por: Gandhi, Manoj, et al.
Publicado: (2010)

Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas
por: Krishnan, Aswini, et al.
Publicado: (2020)

Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer
por: Semsar-Kazerooni, Koorosh, et al.
Publicado: (2022)

BRAFV600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
por: Silver, Jennifer A., et al.
Publicado: (2021)

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Prevalence and aggressiveness of papillary thyroid carcinoma in surgically-treated graves’ disease patients: a retrospective matched cohort study
por: You, Eunice, et al.
Publicado: (2019)

Expression of Ret/PTC1, -2, -3, -delta3 and -4 in German papillary thyroid carcinoma.
por: Mayr, B., et al.
Publicado: (1998)

Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice
por: Jin, L, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_51u321s1iggq47u6pp1smh69s4